Literature DB >> 16052298

Combined thrombophilic risk factors and essential thrombocythemia in patient with recurrent venous thromboembolic episodes-thirty-three-year follow-up.

Nebojsa Antonijevic1, Milica Stanojevic, Rajko Milosevic, Valentina Djordjevic, Milena Jaukovic, Vlada Vukcevic, Mirjana Kovac, Danijela Mikovic, Dragica Radojkovic, Zorana Vasiljevic.   

Abstract

We present the case of a 64 year-old female patient, with a clearly positive family history of venous thromboembolism (VTE), multiple VTE episodes (massive pulmonary embolism, ovarian venous plexus thrombosis, deep venous thrombosis with submassive pulmonary embolism and second deep venous thrombosis) and myocardial infarction. Laboratory tests revealed the resistance to the activated protein C, elevated FVIII and PAI-1. The patient was found to be a heterozygous carrier of FV Leiden, MTHFR C677T and PAI-1 4G/5G mutations. She was diagnosed with essential thrombocythemia at the age of 60. The thirty-three-year follow-up of our patient and detection of recurrent thrombotic episodes in the light of multiple coagulation defects with proved acquired risk factors, contributes to the risk stratification in the group of patients with very high risk. In case of our patient, we stress inadequacy of widely-accepted standard prevention measures. In our opinion, patients with very high risk require additional mechanic and specific medicament methods of VTE prevention.

Entities:  

Mesh:

Year:  2005        PMID: 16052298     DOI: 10.1007/s11239-005-0783-1

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  6 in total

Review 1.  Molecular risk factors for thrombosis.

Authors:  R M Bertina
Journal:  Thromb Haemost       Date:  1999-08       Impact factor: 5.249

Review 2.  Risk factors for venous thrombotic disease.

Authors:  F R Rosendaal
Journal:  Thromb Haemost       Date:  1999-08       Impact factor: 5.249

Review 3.  The potential role of new therapies in deep-vein thrombosis prophylaxis.

Authors:  P Wille-Jørgensen
Journal:  Semin Hematol       Date:  2001-04       Impact factor: 3.851

Review 4.  Unexplored territories in the nonsurgical patient: a look at pregnancy.

Authors:  A Eldor
Journal:  Semin Hematol       Date:  2001-04       Impact factor: 3.851

Review 5.  Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease.

Authors:  J A Caprini; J I Arcelus; J J Reyna
Journal:  Semin Hematol       Date:  2001-04       Impact factor: 3.851

6.  Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity.

Authors:  S Dawson; A Hamsten; B Wiman; A Henney; S Humphries
Journal:  Arterioscler Thromb       Date:  1991 Jan-Feb
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.